| B-03 Nigel Klein A biological perspective on immune response to drug treatment (intended and unintended effects) Wednesday 09:00-09:40 |
| B-04 Hans Peter Grimm Intricate PK and PD for the novel immunocytokine CEA-IL2v and their pre-clinical to clinical translation Wednesday 09:40-10:00 |
| B-05 Kirill Peskov Investigation of anti-CTLA-4 immuno-oncology therapy through a quantitative systems pharmacology model Wednesday 10:00-10:20 |
